OCA
PALI icon

Octagon Capital Advisors’s Palisade Bio PALI Stock Holding History

Octagon Capital Advisors’s Portfolio PALI Stock Details PALI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18M Buy
10,276,317
+708,419
+7% +$1.29M 1.99% 16
2025
Q4 		$22.5M Buy
+9,567,898
New +$18.4M 2.73% 13

Other funds holding PALI

Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
BGI
B Group Inc Dallas, Texas $135M AUM 80% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

Octagon Capital Advisors's PALI Position: Q1 2026 in Review

Octagon Capital Advisors increased its Palisade Bio (PALI) stake by 7.4% in Q1 2026, buying an estimated $1.29M and bringing the position to 10,276,317 shares worth $18M. The position accounts for 1.99% of the portfolio, ranked #16.

Octagon Capital Advisors first reported a position in PALI in Q4 2025 and has held it in 2 quarters since. The position peaked at $22.5M in Q4 2025. 96 funds tracked by Wall St. Rank hold PALI as of Q1 2026.

  • Octagon Capital Advisors held 10,276,317 shares of Palisade Bio worth $18M as of Q1 2026.
  • Octagon Capital Advisors bought 708,419 Palisade Bio shares in Q1 2026, an estimated $1.29M.
  • Palisade Bio made up 1.99% of Octagon Capital Advisors's portfolio in Q1 2026, its #16 holding.
  • Octagon Capital Advisors first reported a position in Palisade Bio in Q4 2025 and has held it in 2 quarters since.
  • Octagon Capital Advisors's Palisade Bio position peaked at $22.5M in Q4 2025.
  • 96 funds tracked by Wall St. Rank held Palisade Bio as of Q1 2026.

Based on Octagon Capital Advisors's 13F filing for Q1 2026, filed 15 May 2026.